For patients at risk of thrombosis, administer GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

For patients at risk of thrombosis, administer GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

For patients at risk of thrombosis, administer GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs...

2024年4月19日 · The recommended initial infusion rate is 2 mg/kg/min (0.02 mL/kg/min). If the infusion is well tolerated, the rate may be gradually increased to a maximum of 8 mg/kg/min (0.08 mL/kg/min). For patients judged to be at risk for renal dysfunction or thrombosis, administer GAMUNEX-C at the minimum infusion rate practicable.

For patients at risk of thrombosis, administer XEMBIFY and GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess …

progressions (up to 0.08 mL/kg/min) are recommended for all initial infusions. If initial infusion tolerated well in Primary Immune Deficiency and Secondary Immune Deficiency recipients, the recommended rate progression for subsequent infusi.

Adults ≥17 years: Infusions 1–2: ≤20 mL/hr/site. Subsequent Infusions: Gradually increase as tolerated by approximately 10 mL/hr/ site every 2-4 weeks up to a maximum of 52 mL/hr/site. Age 2-16 years: Infusions 1-2: ≤15 mL/hr/site.

GAMUNEX® 10% is a human intravenous (IV) immunoglobulin (IVIg) solution for IV infusion. It is available in Australia in bottles containing 5g (50 mL), 10g (100 mL) and 20g (200 mL) of IVIg. Follow Health Service protocols where available & refer to the product information (PI).

Primary humoral immunodeficiency disorders: Gamunex-C®: I.V.: 300-600 mg/kg every 3-4 weeks; adjusted based on dosage and interval in conjunction with monitored serum IgG concentrations and clinical response. SubQ infusion: Begin 1 …

formula: Rate (mL/kg/min) x Weight (kg) x 60 min/hr = Hourly infusion rate (mLs/hr). Perform a DOUBLE CHECK of all calculations. Perform assessment including vital signs at a minimum: pre-infusion, 15 minutes after infusion initiated, with each rate increase, upon